GlassScriptPhysician profile
Angela Grigos
NPI 1184043747
$2,665.51
in general payments reported to CMS, 2019-2025
25 companies · $1,038 in 2025
The $1,038 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $101 · 2021: $89.45 · 2022: $128 · 2023: $78.11 · 2024: $828 · 2025: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,703 · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,702.56 |
| Education | $240.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $325.24 | 2019-2024 | Welireg, Keytruda, Verquvo |
| Incyte Corporation | $289.19 | 2024-2025 | Jakafi, Jakafi |
| Daiichi Sankyo INC. | $272.14 | 2024-2025 | Enhertu, Datroway |
| Bayer Healthcare Pharmaceuticals INC. | $262.86 | 2020-2025 | |
| Pfizer INC. | $244.75 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2024 | Fruzaqla |
| Janssen Biotech, INC. | $119.85 | 2025 | Rybrevant, Carvykti |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $114.39 | 2019-2024 | Lifevest |
| Gilead Sciences, INC. | $113.94 | 2025 | Trodelvy |
| Exelixis INC. | $104.52 | 2025 | Cabometyx |
| Seagen INC. | $99.99 | 2024 | |
| Novocure INC. | $80.80 | 2025 | Optune Lua (Novottf-200t) |
| E.R. Squibb & Sons, L.L.C. | $79.20 | 2019-2025 | Opdivo |
| Regeneron Healthcare Solutions, INC. | $61.41 | 2021-2023 | Dupixent |
| Shionogi INC | $58.54 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $46.51 | 2024-2025 | |
| Janssen Research & Development, LLC | $40.05 | 2025 | |
| Pharmaessentia USA Corporation | $39.45 | 2024-2025 | Besremi |
| Abbvie INC. | $38.67 | 2025 | |
| Genmab U.S., INC. | $36.14 | 2024 | Epkinly |
| Janssen Pharmaceuticals, INC | $25.25 | 2023 | Xarelto |
| Taiho Oncology, INC. | $25.00 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $24.93 | 2024 | |
| Myriad Genetic Laboratories, INC. | $20.90 | 2024 | Precisetumor |
| Novartis Pharmaceuticals Corporation | $16.79 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Grigos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.